John P. Fruehauf - Publications

Biomedical Engineering - Ph.D. University of California, Irvine, Irvine, CA 
Biomedical Engineering

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP. HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular Cancer Research : McR. PMID 31088908 DOI: 10.1158/1541-7786.MCR-18-1109  0.48
2018 Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. PMID 29943192 DOI: 10.1007/s00280-018-3624-6  0.48
2014 Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology. 74: 1279-89. PMID 25336084 DOI: 10.1007/s00280-014-2606-6  1
2013 Eroglu Z, Fruehauf JP. A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemotherapy and Pharmacology. 72: 263-7. PMID 23636451 DOI: 10.1007/s00280-013-2178-x  1
2013 Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biology : Journal of the International Society For Matrix Biology. 32: 123-32. PMID 23202046 DOI: 10.1016/j.matbio.2012.11.010  1
2012 Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 126: 375-80. PMID 22683587 DOI: 10.1016/j.ygyno.2012.06.002  0.4
2010 Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 13: 305-15. PMID 20927579 DOI: 10.1007/s10456-010-9187-8  1
2010 Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90. PMID 20870280 DOI: 10.1016/j.ygyno.2010.08.016  1
2010 Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecologic Oncology. 119: 417-21. PMID 20846714 DOI: 10.1016/j.ygyno.2010.08.010  1
2010 Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 452-8. PMID 19913895 DOI: 10.1016/j.ygyno.2009.10.062  0.4
2010 Fruehauf JP. Patient-specific tumor biology-based selection of ovarian cancer therapy Therapy. 7: 213-216. DOI: 10.2217/thy.10.20  1
2009 Trapp V, Lee K, Doñate F, Mazar AP, Fruehauf JP. Redox-related antimelanoma activity of ATN-224. Melanoma Research. 19: 350-60. PMID 22760066 DOI: 10.1097/CMR.0b013e32832c6324  1
2009 Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 112: 583-9. PMID 19110305 DOI: 10.1016/j.ygyno.2008.11.013  1
2008 Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Review of Anticancer Therapy. 8: 1751-7. PMID 18983235 DOI: 10.1586/14737140.8.11.1751  1
2008 Mathews MS, Linskey ME, Hasso AN, Fruehauf JP. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surgical Neurology. 70: 649-52; discussion 6. PMID 18261776 DOI: 10.1016/j.surneu.2007.06.029  1
2007 Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation Oncogene. 26: 1188-1200. PMID 16936779 DOI: 10.1038/sj.onc.1209901  1
2006 Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V. Mathematical modeling of cancer progression and response to chemotherapy. Expert Review of Anticancer Therapy. 6: 1361-76. PMID 17069522 DOI: 10.1586/14737140.6.10.1361  1
2006 Nguyen H, Tran A, Lipkin S, Fruehauf JP. Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Investigation. 24: 630-9. PMID 16982469 DOI: 10.1080/07357900600896281  1
2005 Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA, Fruehauf JP. Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study. Gynecologic Oncology. 99: 84-91. PMID 16109440 DOI: 10.1016/j.ygyno.2005.05.043  1
2005 Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecologic Oncology. 98: 360-8. PMID 16000215 DOI: 10.1016/j.ygyno.2005.04.036  1
2005 Fruehauf JP, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3641-3; author reply. PMID 15908686 DOI: 10.1200/JCO.2005.05.281  1
2004 Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecologic Oncology. 92: 160-6. PMID 14751152 DOI: 10.1016/j.ygyno.2003.09.030  0.4
2002 Monk BJ, Burger RA, Parker R, Radany EH, Redpath L, Fruehauf JP. Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecologic Oncology. 87: 193-9. PMID 12477451 DOI: 10.1006/gyno.2002.6818  0.4
2002 Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP. Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Research and Treatment. 71: 95-102. PMID 11881914 DOI: 10.1023/A:1013843912560  1
2000 Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP. Biomarker conservation in primary and metastatic epithelial ovarian cancer Gynecologic Oncology. 78: 130-136. PMID 10926791 DOI: 10.1006/gyno.2000.5837  0.4
1999 Khoury H, Kyshtoobayeva A, Mechetner E, Burger R, Monk B, Fruehauf JP. Thrombospondin-1 may regulate angiogenesis in cervical carcinoma Journal of Investigative Medicine. 47: 136A.  1
Show low-probability matches.